Roche Acquires Foundation Medicine and Brings Precision Oncology’s Data Layer Fully In-House

01 · What happened

Announced 19 June 2018. Completed through a tender offer and second-step merger in July 2018.

Roche bought the Foundation Medicine shares it did not already own for $137 in cash per share, a $2.4bn minority buyout that put a $5.3bn fully diluted value on the cancer-genomics company. The commercial significance was larger than the legal step: Roche moved from majority owner and distribution partner to sole owner of a platform connecting genomic profiling, companion diagnostics, oncology drug development and clinical decision support. 1 (opens in a new tab)

The deal followed three years in which Roche had used a majority stake, an R&D collaboration and ex-US commercial rights to build the relationship. At signing, Roche controlled approximately 56.6% of Foundation Medicine’s outstanding shares. The remaining purchase consolidated an asset already woven into Roche’s personalised-healthcare strategy. 2 (opens in a new tab)

02 · Terms

The consideration and legal path were explicitly disclosed. The underlying merger agreement and 14D-9 provide the operative record.

Roche disclosed all core economic terms. Financing sources, break-fee terms and retention arrangements were not itemised in the announcement materials reviewed for this page. That is the only disclosure gap relevant to the headline transaction structure.

03 · The asset

Foundation Medicine offered a comprehensive genomic profiling platform rather than a single diagnostic product.

Foundation Medicine’s clinical assays profiled tumour tissue and blood to identify genomic alterations, match patients with relevant targeted therapies and immunotherapies, and surface clinical-trial options. Its business combined physician-ordered testing with work for biopharma customers, including clinical-study testing, biomarker work and companion diagnostic development. 3 (opens in a new tab)

Clinical engine

FoundationOne CDx

The FDA approved the broad companion diagnostic assay for solid tumours in November 2017. CMS followed with nationwide Medicare coverage in March 2018 for eligible advanced-cancer patients.

Biopharma engine

Data that informs development

Pharma customers used the platform for profiling, trial design, biomarker discovery and companion diagnostic programmes, creating a customer base alongside clinical testing.

Data engine

FoundationCORE

Each profiled tumour added to an evolving molecular information base. The strategic value sat in the loop between testing volume, evidence generation and oncology R&D.

Roche’s current profile says Foundation Medicine remains an independent affiliate with more than 1,700 employees and CGP tests analysing more than 300 cancer-related genes. That scale is a later outcome, not a 2018 deal metric, but it illustrates the platform Roche chose to consolidate. 4 (opens in a new tab)

04 · Unit economics

The key valuation tension was straightforward: rapid revenue growth and a widening data moat against meaningful operating losses and capital needs.

Foundation Medicine reported $152.9m of 2017 revenue, up 31% year on year, and $57.0m for the second quarter of 2018, up 63% year on year. Annualising the second-quarter run rate produces $228.0m, which puts the $5.3bn company value at 23.2× annualised Q2 revenue. Using 2017 reported revenue, the same figure is 34.7×. Both are Acquiry calculations and are revenue reference points, not EBITDA multiples. 5 (opens in a new tab) 6 (opens in a new tab)

The company was still consuming cash. In the first half of 2018 it reported a $70.8m net loss and $60.2m of net cash used in operating activities. Roche funding was already part of the capital structure, with $110m of non-current indebtedness to Roche at 30 June 2018. The buyout therefore secured an operating asset and removed the public-market funding question at the same time. 6 (opens in a new tab)

Acquiry calculation$5.3bn total company value ÷ $228.0m annualised Q2 2018 revenue = 23.2×Annualised revenue is a reference framework, not company guidance.

05 · Buyer rationale

The 2015 alliance had already outlined the logic. The 2018 buyout brought control, duration and capital allocation inside the group.

01

Secure the diagnostic layer for personalised oncology

FoundationOne CDx had a recently established regulatory and reimbursement foothold. Ownership aligned the diagnostic platform with Roche’s oncology portfolio and companion-diagnostic agenda.

02

Turn distribution rights into operating control

Roche already held ex-US commercialisation rights for several tests. Full ownership gave it a single decision path for global launch, investment and product evolution.

03

Protect the molecular-data feedback loop

CGP testing, biopharma research and companion diagnostics compounded the value of a common molecular information base. Control reduces coordination cost across those activities.

04

Fund the next scale phase away from quarterly-market pressure

Foundation Medicine’s revenue momentum came with substantial research, laboratory and commercial spend. A private affiliate structure matched that investment profile.